Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/21482
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Göktalay, Gökhan | - |
dc.contributor.author | Millington, William R. | - |
dc.date.accessioned | 2021-08-20T05:52:28Z | - |
dc.date.available | 2021-08-20T05:52:28Z | - |
dc.date.issued | 2005-11 | - |
dc.identifier.citation | Çavun, S. vd. (2005). "Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal". Journal of Pharmacology and Experimental Therapeutics, 315(2), 949-958. | en_US |
dc.identifier.issn | 0022-3565 | - |
dc.identifier.uri | https://doi.org/10.1124/jpet.105.091553 | - |
dc.identifier.uri | https://jpet.aspetjournals.org/content/315/2/949 | - |
dc.identifier.uri | http://hdl.handle.net/11452/21482 | - |
dc.description.abstract | Glycyl-glutamine (Gly-Gln; beta-endorphin(30-31)) is an endogenous dipeptide synthesized from beta-endorphin(1-31). Previous investigations have shown that Gly-Gln inhibits the cardiovascular and respiratory depression caused by morphine and beta-endorphin(1-31), but it does not interfere with opioid analgesia. In this study, we tested whether Gly-Gln administration would influence morphine-induced conditioned place preference, tolerance, dependence, or withdrawal. For place preference experiments, rats were conditioned with morphine sulfate (2.5 mg/kg i.p.) or saline on alternate days for 6 days and tested on day 7. Glycyl-glutamine (1-100 nmol i.c.v.) pretreatment inhibited acquisition of a conditioned place preference to morphine significantly. Glycyl-glutamine (100 nmol i.c.v.) also blocked expression of a pre-established morphine place preference, but it did not interfere with acquisition of a conditioned place preference to palatable food, and it did not produce place preference or aversion when given alone to morphine-naive animals. To induce antinociceptive tolerance, rats were treated with morphine (10 mg/kg i.p.) twice daily for 7 days, and morphine antinociception was evaluated with the tail-flick test. Glycylglutamine (100 nmol i.c.v.) pretreatment delayed the onset of morphine tolerance significantly and partially reversed pre-established tolerance. Morphine dependence and withdrawal were assessed by measuring naloxone-precipitated withdrawal symptoms. Glycyl-glutamine inhibited the development of morphine dependence when given to rats twice daily immediately before they received morphine (10 mg/kg i.p.) and suppressed withdrawal symptoms of rats with subcutaneously implanted morphine pellets when administered 5 min before withdrawal was induced with naloxone. Glycyl-glutamine thus attenuates morphine-induced conditioned place preference, tolerance, dependence, and withdrawal without compromising morphine analgesia. | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute on Drug Abuse (NIDA) - DA018029 | en_US |
dc.description.sponsorship | United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute on Drug Abuse (NIDA) European Commission - R41DA018029 | en_US |
dc.language.iso | en | en_US |
dc.publisher | Amer Soc Pharmacology Experimental Therapeutics | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Naturally-occurring antagonist | en_US |
dc.subject | Acetylcholinesterase | en_US |
dc.subject | Cardiorespiratory depression | en_US |
dc.subject | Physical-dependence | en_US |
dc.subject | Rat-brain | en_US |
dc.subject | Proopiomelanocortin | en_US |
dc.subject | Receptors | en_US |
dc.subject | Opioids | en_US |
dc.subject | Beta-endorphin-(1-27) | en_US |
dc.subject | Antinociception | en_US |
dc.subject | Pharmacology & pharmacy | en_US |
dc.title | Glycyl-glutamine, an endogenous beta-endorphin-derived peptide, inhibits morphine-induced conditioned place preference, tolerance, dependence, and withdrawal | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000232681300054 | tr_TR |
dc.identifier.scopus | 2-s2.0-27144518063 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Farmakoloji ve Klinik Farmakoloji Anabilim Dalı. | tr_TR |
dc.identifier.startpage | 949 | tr_TR |
dc.identifier.endpage | 958 | tr_TR |
dc.identifier.volume | 315 | tr_TR |
dc.identifier.issue | 2 | tr_TR |
dc.relation.journal | Journal of Pharmacology and Experimental Therapeutics | en_US |
dc.contributor.buuauthor | Çavun, Sinan | - |
dc.contributor.researcherid | AAC-9702-2019 | tr_TR |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.identifier.pubmed | 16079299 | tr_TR |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q1 | en_US |
dc.contributor.scopusid | 6507468595 | tr_TR |
dc.subject.scopus | Aging; Amoxicillin; Contractility Invitro | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.